BACKGROUND AND PURPOSE: Endothelin-1 (ET-1) reduces insulin-stimulated glucose uptake in skeletal muscle, inducing insulin resistance. Here, we have determined the molecular mechanisms underlying negative regulation by ET-1 of insulin signalling. EXPERIMENTAL APPROACH: We used the rat L6 skeletal muscle cells fully differentiated into myotubes. Changes in the phosphorylation of Akt was assessed by Western blotting. Effects of ET-1 on insulin-stimulated glucose uptake was assessed with [(3) H]-2-deoxy-d-glucose ([(3) H]2-DG). The C-terminus region of GPCR kinase 2 (GRK2-ct), a dominant negative GRK2, was overexpressed in L6 cells using adenovirus-mediated gene transfer. GRK2 expression was suppressed by transfection of the corresponding short-interfering RNA (siRNA). KEY RESULTS: In L6 myotubes, insulin elicited sustained Akt phosphorylation at Thr(308) and Ser(473) , which was suppressed by ET-1. The inhibitory effects of ET-1 were prevented by treatment with a selective ETA receptor antagonist and a Gq protein inhibitor, overexpression of GRK2-ct and knockdown of GRK2. Insulin increased [(3) H]2-DG uptake rate in a concentration-dependent manner. ET-1 noncompetitively antagonized insulin-stimulated [(3) H]2-DG uptake. Blockade of ETA receptors, overexpression of GRK2-ct and knockdown of GRK2 prevented the ET-1-induced suppression of insulin-stimulated [(3) H]2-DG uptake. In L6 myotubes overexpressing FLAG-tagged GRK2, ET-1 facilitated the interaction of endogenous Akt with FLAG-GRK2. CONCLUSIONS AND IMPLICATIONS: Activation of ETA receptors with ET-1 suppressed insulin-induced Akt phosphorylation at Thr(308) and Ser(473) and [(3) H]2-DG uptake in a GRK2-dependent manner in skeletal muscle cells. These findings suggest that ETA receptors and GRK2 are potential targets for overcoming insulin resistance.
BACKGROUND AND PURPOSE:Endothelin-1 (ET-1) reduces insulin-stimulated glucose uptake in skeletal muscle, inducing insulin resistance. Here, we have determined the molecular mechanisms underlying negative regulation by ET-1 of insulin signalling. EXPERIMENTAL APPROACH: We used the rat L6 skeletal muscle cells fully differentiated into myotubes. Changes in the phosphorylation of Akt was assessed by Western blotting. Effects of ET-1 on insulin-stimulated glucose uptake was assessed with [(3) H]-2-deoxy-d-glucose ([(3) H]2-DG). The C-terminus region of GPCR kinase 2 (GRK2-ct), a dominant negative GRK2, was overexpressed in L6 cells using adenovirus-mediated gene transfer. GRK2 expression was suppressed by transfection of the corresponding short-interfering RNA (siRNA). KEY RESULTS: In L6 myotubes, insulin elicited sustained Akt phosphorylation at Thr(308) and Ser(473) , which was suppressed by ET-1. The inhibitory effects of ET-1 were prevented by treatment with a selective ETA receptor antagonist and a Gq protein inhibitor, overexpression of GRK2-ct and knockdown of GRK2. Insulin increased [(3) H]2-DG uptake rate in a concentration-dependent manner. ET-1 noncompetitively antagonized insulin-stimulated [(3) H]2-DG uptake. Blockade of ETA receptors, overexpression of GRK2-ct and knockdown of GRK2 prevented the ET-1-induced suppression of insulin-stimulated [(3) H]2-DG uptake. In L6 myotubes overexpressing FLAG-tagged GRK2, ET-1 facilitated the interaction of endogenous Akt with FLAG-GRK2. CONCLUSIONS AND IMPLICATIONS: Activation of ETA receptors with ET-1 suppressed insulin-induced Akt phosphorylation at Thr(308) and Ser(473) and [(3) H]2-DG uptake in a GRK2-dependent manner in skeletal muscle cells. These findings suggest that ETA receptors and GRK2 are potential targets for overcoming insulin resistance.
Authors: T Imamura; P Vollenweider; K Egawa; M Clodi; K Ishibashi; N Nakashima; S Ugi; J W Adams; J H Brown; J M Olefsky Journal: Mol Cell Biol Date: 1999-10 Impact factor: 4.272
Authors: C Schalin-Jäntti; H Yki-Järvinen; L Koranyi; R Bourey; J Lindström; P Nikula-Ijäs; A Franssila-Kallunki; L C Groop Journal: Diabetologia Date: 1994-04 Impact factor: 10.122
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Derek B J Bone; Jaroslawna Meister; Jonas R Knudsen; Diptadip Dattaroy; Amanda Cohen; Regina Lee; Huiyan Lu; Daniel Metzger; Thomas E Jensen; Jürgen Wess Journal: Diabetes Date: 2019-04-01 Impact factor: 9.461
Authors: Thomas J Jurrissen; Zachary I Grunewald; Makenzie L Woodford; Nathan C Winn; James R Ball; Thomas N Smith; Andrew A Wheeler; Arthur L Rawlings; Kevin F Staveley-O'Carroll; Yan Ji; William P Fay; Pierre Paradis; Ernesto L Schiffrin; Victoria J Vieira-Potter; Paul J Fadel; Luis A Martinez-Lemus; Jaume Padilla Journal: Am J Physiol Endocrinol Metab Date: 2019-07-16 Impact factor: 4.310
Authors: Benjamin E Young; Jaume Padilla; Stine H Finsen; Paul J Fadel; Stefan P Mortensen Journal: Endocrinology Date: 2022-03-01 Impact factor: 4.736
Authors: Chaterina Sujana; Veikko Salomaa; Frank Kee; Jochen Seissler; Pekka Jousilahti; Charlotte Neville; Cornelia Then; Wolfgang Koenig; Kari Kuulasmaa; Jaakko Reinikainen; Stefan Blankenberg; Tanja Zeller; Christian Herder; Ulrich Mansmann; Annette Peters; Barbara Thorand Journal: Cardiovasc Diabetol Date: 2022-06-09 Impact factor: 8.949